When CAC Tests Are Useful and When They Are Not
This video clip is from episode #185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we…
Peter on why early prevention of atherosclerosis is critical
This video clip is from episode #185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we…
Preventing Atherosclerosis: 2 Fatal Flaws with the “10 Year Risk” Approach
This video clip is from episode #185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way…
#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#67 – AMA #8: DNA tests, longevity genes, metformin, fasting markers, salt, inflammation, and more
“If you are genetically blessed to become a centenarian, the gift you got is that you have genes that delay your receipt of chronic disease by what appears to be about 20 years.” — Peter Attia
#22 – Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins
“Here’s something that’s going to shock you: in an average person, anywhere from 30 to 60 percent of the cholesterol in that LDL particle arrived via an HDL particle.” –Tom Dayspring
#20 – Tom Dayspring, M.D., FACP, FNLA – Part I of V: an introduction to lipidology
“Illustrating things made me understand . . . I just learned by illustrating.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).